Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Vanishing Twin Pregnancies

NCT05004337 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to collect blood samples from women carrying a vanishing twin pregnancy to further develop Natera's non-invasive prenatal screening test to provide information about possible chromosomal conditions for the living twin

Study Locations (20)

New York

  • NYU Long Island — Mineola
  • NYU Langone — New York
  • Icahn School of Medicine at Mount Sinai Hospital — New York
  • Columbia University — New York
  • Weill Cornell Medicine — New York
  • Montefiore Medical Center — The Bronx

California

  • Center for Fetal Medicine & Women's Ultrasound — Los Angeles
  • Stanford — Palo Alto

Michigan

  • University of Michigan — Ann Arbor
  • Beaumont — Royal Oak

New Jersey

  • Hackensack — Neptune City
  • St. Peter's University Hospital — New Brunswick

Pennsylvania

  • Lehigh Valley Health Network — Allentown
  • University of Pennsylvania — Philadelphia

Colorado

  • University of Colorado — Aurora

Connecticut

  • Yale — New Haven

Delaware

  • Christiana Care — Newark

Trial Details

FieldValue
Enrollment Target 126 participants
Start Date 2021-07-22
Est. Completion 2023-11-29

Sponsor

Natera

40 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05004337

The ClinicalTrials.gov registry entry for NCT05004337 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Natera, which has 40 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 4 conditions, with Trisomy 21 appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05004337 reports 20 study locations spanning 11 distinct geographic areas — top geographies include New York, California, Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05004337 about?

NCT05004337 is a clinical study titled "Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Vanishing Twin Pregnancies". The purpose of this study is to collect blood samples from women carrying a vanishing twin pregnancy to further develop Natera's non-invasive prenatal screening test to provide information about possible chromosomal conditions for the living twin

What is the current status of trial NCT05004337?

This trial is currently completed. The enrollment target is 126 participants. The study started on 2021-07-22. Estimated completion is 2023-11-29.

What conditions does trial NCT05004337 study?

This clinical trial studies the following conditions: Trisomy 21, Trisomy 18, Trisomy 13, Vanishing Twin. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT05004337?

This trial is sponsored by Natera, which has 40 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05004337 being conducted?

This trial has 20 study locations across California, Colorado, Connecticut, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial